MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
52.62
-1.68 (-3.09%)
At close: Sep 12, 2025, 4:00 PM EDT
53.67
+1.05 (2.00%)
After-hours: Sep 12, 2025, 7:36 PM EDT
MLTX Employees
MoonLake Immunotherapeutics had 100 employees as of December 31, 2024. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$1,761,605
Market Cap
3.34B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MLTX News
- 17 days ago - 2 Logical Mid-Cap Biotech Buyout Targets - Seeking Alpha
- 5 weeks ago - MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest - Seeking Alpha
- 3 months ago - Merck held talks to buy biotech MoonLake for over $3 billion, FT reports - Reuters
- 4 months ago - MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 months ago - MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - GlobeNewsWire
- 5 months ago - MoonLake Immunotherapeutics: A Buy At Dips - Seeking Alpha
- 5 months ago - MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates - GlobeNewsWire